On Wednesday, Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $137.94 which represents a slight increase of $7.44 or 5.70% from the prior close of $130.5. The stock opened ...
The rise in SRPT's share price can be attributed to the encouraging sales performance of its recently approved one-shot gene therapy for DMD.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards ...
Bernstein lowered the firm’s price target on Arrowhead (ARWR) to $24 from $27 and keeps a Market Perform rating on the shares. The company’s ...
PTC Therapeutics faces significant risks with its key revenue sources, Translarna and Emflaza. Find out why I am sticking ...
Investor's Business Daily on MSN16h
Sarepta Therapeutics Sees RS Rating Rise To 75A Relative Strength Rating upgrade for Sarepta Therapeutics shows improving technical performance. Will it continue?
The head of MI6 says British security will be "jeopardised" if Putin is allowed to succeed in Ukraine, as he warned the spy agency has already uncovered a Russian sabotage campaign in Europe.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback